Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Investigational mineralocorticoid receptor antagonist KBP-5074 evaluated in phase I trial

Nov. 17, 2017

Achillion reports preliminary data from phase II study of ACH-4471 in C3G

Nov. 15, 2017

TP-0469711 demonstrates promising activity as a new therapeutic for hyperphosphatemia

Nov. 14, 2017

Novel antibody against TGF-beta1 shows efficacy without cardiotoxicity in fibrosis model

Nov. 14, 2017

Wound healing improved with SNF-472 in hemodialysis patients with calciphylaxis

Nov. 13, 2017

FDA accepts Otsuka's resubmitted NDA for tolvaptan

Nov. 10, 2017

FDA approves Keryx's Auryxia in new indication

Nov. 8, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Klotho Therapeutics announces series A financing to advance patent pending version of Klotho

Nov. 7, 2017

Ono Pharmaceutical divulges novel voltage-gated channel activators

Nov. 6, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.